Navigation Links
VCU study: Researchers discover a drug combination that shrinks tumors in vivo
Date:9/27/2010

RICHMOND, Va. (Sept. 27, 2010) Virginia Commonwealth University School of Medicine and VCU Massey Cancer Center researchers have shown that the impotence drug Viagra, in combination with doxorubicin, a powerful anti-cancer drug, enhances its anti-tumor efficacy in prostate cancer while alleviating the damage to the heart at the same time.

For more than four decades the chemotherapeutic agent doxorubicin has been used to treat a number of human cancers, including that of the prostate. Despite doxorubicin's clinical efficacy for cancer treatment, its use is associated with irreversible heart damage, often presenting several years after treatment stops. Researchers have been working over the past 15 years to find an optimal therapeutic intervention for protecting the heart against the cytotoxicity associated with doxorubicin.

In the study published online the week of Sept. 27 in the Early Edition of the journal Proceedings of the National Academy of Sciences, researchers using a variety of powerful in vitro and in vivo approaches, have shown that a combination of Viagra, generically known as sildenafil, and doxorubcin significantly enhances the generation of reactive oxygen species that trigger cell death, or apoptosis, in prostate cancer cells. They also observed that the combination did not harm the normal, healthy prostate epithelial cells.

"We believe sildenafil could be an excellent candidate for incorporation into cancer treatment protocols with the potential of enhancing the anti-tumor efficacy, while protecting the heart against both short term and long term damage from doxorubicin," said principal investigator Rakesh C. Kukreja, Ph.D., scientific director of the VCU Pauley Heart Center and the Eric Lipman professor in cardiology in the VCU School of Medicine, and Anindita Das, Ph.D., assistant professor in the Department of Internal Medicine the VCU School of Medicine.

Kukreja is excited about the potential translational impact of this work. "My team and I are hoping to move the research forward to a clinical trial and plans are under way to do so," he said. The clinical trial would evaluate the effectiveness of the drug combination in cancer patients.

Kukreja's laboratory is one of the first to explore the area of preconditioning. This preconditioning effect was modeled in his lab by "pretreating" mice with doses of sildenafil which also increases therapeutic levels of nitric oxide in the heart.

A preconditioned or pretreated heart has an improved ability to produce nitric oxide and directly improves a patient's outcome following a heart attack. Generally, damage following a heart attack is related to an inability to recover from lack of oxygen.


'/>"/>

Contact: Sathya Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Study: Choice between stroke-prevention procedures influenced by patient age
2. UNC study: Obese 3-year-olds show early warning signs for future heart disease
3. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
4. Henry Ford Hospital study: Shoulder function not fully restored after surgery
5. Study: Federal funds support health depts., but leadership is key
6. Study: Kidney disease a big risk for younger, low-income minorities
7. Study: Mechanomyography to be accurate in detecting nerves during minimally invasive spine surgery
8. Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids
9. Study: Child health may suffer in strong economy
10. Study: Social influence playing role in surging autism diagnoses
11. Children's Rights Group Agrees with New Study: Infant Circumcision Causes 100 Deaths Each Year in US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... trials with the announcement that it is one of the early adopters completing EU-U.S. ... Shield Framework is designed to provide companies on both sides of the Atlantic with ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, ... the most comprehensive mental health systems reform legislation in more than fifty years. ... and the commitment of our elected officials to improving mental health services and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... their bodies, a researcher at the Icahn School of Medicine at Mount Sinai ... study found that when young children are exposed to secondhand marijuana smoke, measurable ...
(Date:12/7/2016)... CITY, UTAH (PRWEB) , ... December 07, 2016 ... ... today announced the release of Smart Device Remote Control through a new partnership ... across all platforms and strengthens its mobile solutions to help businesses maximize their ...
(Date:12/7/2016)... Georgia (PRWEB) , ... December ... ... today it has acquired Presence Technology, S.L. (“Presence”) for a purchase price ... price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 million. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
Breaking Medicine Technology: